Volume 4.36 | Sep 13

Mammary Cell News 4.36 September 13, 2012
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY

FAM83A Confers EGFR-TKI Resistance in Breast Cancer Cells and in Mice
Using a screen to measure reversion of malignant cells into phenotypically nonmalignant cells in 3D gels, investigators identified FAM83A as a candidate cancer-associated gene capable of conferring resistance to EGFR-tyrosine kinase inhibitors (TKIs). FAM83A overexpression in cancer cells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and in animals. [J Clin Invest]
Abstract | Press Release


[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Hypoxia-Inducible Factor 1-Dependent Expression of Platelet-Derived Growth Factor B Promotes Lymphatic Metastasis of Hypoxic Breast Cancer Cells
The authors showed that hypoxia-inducible factor 1 promotes lymphatic metastasis of breast cancer by direct transactivation of the gene encoding platelet-derived growth factor B, which has proliferative and chemotactic effects on lymphatic endothelial cells. [Proc Natl Acad Sci USA] Abstract | Press Release

The Hippo Pathway Target, YAP, Promotes Metastasis through Its TEAD-Interaction Domain
Researchers demonstrated that increased Yes-associated protein (YAP) activity is potently prometastatic in breast cancer and melanoma cells. Using a Luminex-based approach to multiplex in vivo assays, it was determined that the domain of YAP that interacts with the TEAD/TEF family of transcription factors but not the WW domains or PDZ-binding motif, is essential for YAP-mediated tumor growth and metastasis. [Proc Natl Acad Sci USA]
Full Article

Estrogen-Induced Upregulation and 3′-UTR Shortening of CDC6
Scientists investigated whether 17 ß-estradiol (E2) induces alternative polyadenylation and 3′-UTR shortening to activate proto-oncogenes in estrogen receptor positive breast cancers. The initial probe based screen of independent expression arrays suggested upregulation and 3′-UTR shortening of an essential regulator of DNA replication, CDC6, upon E2 treatment. [Nucl Acids Res] Abstract | Full Article

High-Fat or Ethinyl-Oestradiol Intake during Pregnancy Increases Mammary Cancer Risk in Several Generations of Offspring
Researchers investigated whether feeding pregnant rats a high-fat (HF)- or ethinyl-oestradiol (EE2)-supplemented diet affects carcinogen-induced mammary cancer risk in daughters, granddaughters and great-granddaughters. They showed that mammary tumorigenesis is higher in daughters and granddaughters of HF rat dams and in daughters and great-granddaughters of EE2 rat dams. [Nat Commun]
Abstract | Press Release

Ets-1 Is a Transcriptional Mediator of Oncogenic Nitric Oxide Signaling in Estrogen Receptor-Negative Breast Cancer
The authors recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Here, they examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells. [Breast Cancer Res]
Abstract

CLINICAL RESEARCH

Exposure to Diagnostic Radiation and Risk of Breast Cancer among Carriers of BRCA1/2 Mutations: Retrospective Cohort Study (GENE-RAD-RISK)

In carriers of BRCA1/2 mutations, any exposure to diagnostic radiation before the age of 30 was associated with an increased risk of breast cancer with a dose-response pattern. [BMJ]
Abstract | Press Release

Circulating MicroRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Investigators aimed to establish a panel of circulating microRNAs capable of differentiating metastatic breast cancer cases from healthy controls. [Clin Cancer Res] Abstract

High TWIST1 mRNA Expression is Associated with Poor Prognosis in Lymph Node-Negative and Estrogen Receptor-Positive Human Breast Cancer and Is Co-Expressed with Stromal as well as ECM Related Genes
Researchers investigated whether TWIST homolog 1 (TWIST1) expression predicts disease progression in a large breast cancer cohort with long-term clinical follow-up, and revealed the biology related to TWIST1 mediated disease progression. The biological associations suggest an involvement of the tumor microenvironment in TWIST1’s adverse role in breast cancer. [Breast Cancer Res] Abstract

Mammographic Screening and Breast Cancer Mortality: A Case-Control Study and Meta-Analysis
Researchers conducted a case-control study of breast cancer deaths in Western Australia to evaluate the effect of participation in the BreastScreen Australia program, paying particular attention to potential sources of bias, and undertook an updated meta-analysis of case-control studies. [Cancer Epidemiol Biomarkers Prev] Abstract | Press Release

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

REVIEWS
Cancer Treatment According to BRCA1 and BRCA2 Mutations
This review discusses how the identification of germline mutations associated with significant cancer susceptibility has the potential to change all aspects of an individual’s care, from screening to cancer treatment. [Nat Rev Clin Oncol] Abstract
SCIENCE NEWS

Key Research Highlights Treatment Advances for Early Breast Cancer
Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released. [Press release from the American Society of Clinical Oncology discussing research to be presented at the Breast Cancer Symposium 2012, San Francisco] Press Release

20/20 GeneSystems to Present Data on Biomarker Panel to Improve Efficacy of Targeted Breast Cancer Therapy
20/20 GeneSystems, Inc. will present results of a 45 patient study showing the usefulness of its PredicTOR™ test in predicting response of breast tumors to the drug Herceptin®, which blocks the HER2 pathway that is activated in many breast tumors. [Press release from Business Wire discussing research to be presented at the Breast Cancer Symposium 2012, San Francisco] Press Release

Generex Biotechnology Announces Presentation of Early Results Showing Activity of Cancer Vaccine in Patients with Triple Negative Breast Cancer
Generex Biotechnology Corporation will present early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients. [Press release from Generex Biotechnology Corporation discussing research to be presented at the Breast Cancer Symposium 2012, San Francisco] Press Release

Genomic Health Announces Presentation of Two Oncotype DX® Studies at the 2012 Breast Cancer Symposium
Genomic Health, Inc. will present positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of distant recurrence, disease-free survival, and overall survival in women with node-positive breast cancer who were treated with anthracycline-containing chemotherapy regimens. [Press release from Genomic Health Inc. discussing research to be presented at the Breast Cancer Symposium 2012, San Francisco] Press Release

INDUSTRY NEWS

Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek® NDA Due to Manufacturing Deficiencies
Navidea Biopharmaceuticals, Inc. announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Lymphoseek® Injection. Lymphoseek is a novel agent that has been studied in lymphatic mapping procedures performed to help stage breast cancer and melanoma. [Navidea Biopharmaceuticals Inc.] Press Release

Medical Oncologists’ Perceptions of Newly Launched Perjeta are Very Promising, Despite Initial Concerns of Increased Cost Associated With Combining Two Premium-Priced Monoclonal Antibodies to Treat HER2-Positive Breast Cancer
BioTrends Research Group found that Roche/Genentech’s Perjeta which has a positive initial perception by medical oncologists. Perjeta is a HER-dimerization inhibitor that was approved by the U.S. Food and Drug Administration earlier this year. [BioTrends Research Group] Press Release

Dr. Sophia Rahman to Join Diablo Valley Oncology’s Radiation Program
Sophia Rahman, MD, has recently joined the Diablo Valley Oncology/Hematology Medical Group in their Radiation Oncology Department. She has a special interest in the treatment of breast cancer and the use of stereotactic radiosurgical techniques in the treatment of other cancers. [Diablo Valley Oncology]
Press Release

POLICY NEWS

Obama and Romney Tackle 14 Top Science Questions
Scientific American partnered with grassroots organization ScienceDebate.org to encourage the two main presidential candidates – Barack Obama and Mitt Romney – to answer 14 questions on some of the biggest scientific and technological challenges facing the nation. [Presidential Candidates, United States]
Press Release

U.K. Devotes £10 Million to Open Access Shift
Following up on recommendations to make more research freely available to scientists and the public, the U.K. government pledged £10 million toward making scientific papers open access. [U.K. Government, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Mammary Gland Biology
June 9-14, 2013
Stowe, United States

Visit our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)


Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)


Postdoctoral Position(s) – Receptor Trafficking in Mammary Carcinogenesis (The Beatson Institute for Cancer Research)

Research Associate – Quality Assurance (University of California)

Assistant Professor – Breast Cancer Research (Johns Hopkins University)

Postdoctoral Research Scientist(s) – Breast Cancer Research (The Beatson Institute for Cancer Research)


Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us